Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2023 Earnings Call Transcript

But I think, again, we’re seeing great receptivity on both. Again, primary optometry sees a lot of medical visits that they’re incorporating this in. We are hearing from ophthalmologists that they are certainly going to look for a clean, healthy lid before they do a cataract or LASIK surgery. So those things are starting to take hold. And when you think about things like the guidelines, I think that validates the approach, which gives physicians a lot of confidence. And I think more so being in those guidelines also helps our discussions with the payers. It really positions the product at a standard of care, if you will, in eye care. And I think that helps us in those care negotiations that are ongoing as well. I think in terms of the day-to-day feedback, I’ve been out in the field.

I’m hearing that personally. I know, Bobby, you mentioned you’ve been out in the field, maybe you have a couple other insight software as well here.

Bobak Azamian: Yes. I would just add, I mean, we came back from both major academies, optometry and ophthalmology, in the last several weeks. And the value proposition is very strong, whether it was at our booth or advisory boards for commercial or medical affairs. There’s tremendous interest. And I think as you’re seeing in the data, there is a little more demand from optometry out of the gate. They’ve been already looking at the list probably a little bit more than the ophthalmologist. But we know how collaborative these doctors work together. So when we talk about that hybrid approach, it’s really because in a given clinic, you’ll see optometrists and ophthalmologists working together. That was very striking to me, being out in the field. And then there was 1 question about guidelines I think you had, Frank. Did you want to cover that, Aziz?

Aziz Mottiwala: Yes. I think what we said on the guidelines was that I think that’s important validation for the physician, but again, I think really does validate for the payers. So we’re delighted, I think we anticipate incorporating in other guidelines as well. But the AAO practice patterns, I think, are really important. I mean, I think just for reference to add to that is, those aren’t updated very often, right? Those are updated every handful of years. So to be included this year right after launch is a real testament to the medical efforts that we had, the scientific platform we’ve had out there, and I think it is reflected in that.

Operator: This concludes the Q&A session. I would like to now turn it back to Bobby Azamian for closing remarks.

Bobak Azamian: Thank you all, again, for your time and interest. We really look forward to keeping you updated on our progress as we work diligently to deliver on the promise of XDEMVY. Hope everyone has a great day.

Operator: This concludes today’s conference call. Thank you for participating, and you may now disconnect.